High GR-expressing tumor cell populations are predictably protected against pemetrexed-based chemotherapy due to reversible G1 arrest by Dex, which is part of the standard chemotherapy regimen7 but those cell populations should eventually exhibit permanent cell cycle blockade upon extending Dex treatment. Here, NR3C1 is linked to neoplasm.